Drug Discovery World

NOVEMBER 22, 2022

The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season. . The post New range of influenza antigens for vaccine development appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Development Reagent 52

BioTech 365

JANUARY 6, 2021

Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research BEVERLY, Mass.–(BUSINESS

Reagent 40

Reagent Life Science Research Development 40

Drug Discovery World

FEBRUARY 21, 2024

Mike Evans, Chair of MIP Discovery, said: “MIP Discovery’s synthetic affinity reagents offer an innovative alternative to antibodies, and are better suited for downstream processing of advanced therapies.

Gene Therapy 52

Gene Therapy Gene Reagent Production 52

Roots Analysis

APRIL 5, 2023

In fact, non-viral vectors are significantly less expensive than their virus-based counterparts, implying the potential for use in the development of more affordable gene therapies. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.

Reagent 52

Reagent Marketing Gene Therapy Gene 52

XTalks

JUNE 27, 2022

Leading global medical technology company Becton Dickinson (BD) and Spain’s CerTest Biotec have announced they will be collaborating to develop a molecular diagnostic test for the detection of the monkeypox virus. However, he said the global health agency is closely monitoring the evolving situation.

Development 83

Development In-Vitro Reagent Vaccination 83

pharmaphorum

SEPTEMBER 29, 2022

Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to U.S. If so, developers must develop and execute on a regulatory strategy. Food and Drug Administration (FDA) regulation as a medical device.

Development 104

Development Regulation Production Life Science 104

XTalks

OCTOBER 19, 2023

An assay development scientist combines deep biological and biochemical expertise with practical laboratory skills to develop tests that can answer specific biological questions or drive the drug discovery process. Related: Pharmaceutical Scientist Jobs: What to Know Before Applying What Does an Assay Development Scientist Do?

Scientist 59

Scientist Development Research Compliance 59

BioPharma Reporter

FEBRUARY 21, 2023

Donaldson Company will acquire Isolere Bio: an early-stage biotech that develops novel and proprietary âIsoTagâ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.

Reagent 52

Reagent Manufacturing Development 52

Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus’s technologies will be a complementary addition to Satorius’s cell culture media and development of gene therapeutics.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

Roots Analysis

JUNE 1, 2022

The pandemic has specifically resulted in enhanced research and development activities in the field of biotechnology. Recent technological advancements have led to development of novel DNA cloning kits and reagents, which are cost-effective, faster and more efficient than conventional methods. DNA Cloning Reagents Market.

DNA 52

DNA Genetics Reagent Marketing 52

FDA Law Blog

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023.

Reagent 59

Reagent Manufacturing Production Gene Therapy 59

Drug Discovery World

OCTOBER 18, 2023

The research team, led by Professor Steve Watson and Dr Eleyna Martin, developed antibody fragments called nanobodies and crosslinked these to make ligands to four platelet receptors (GPVI, CLEC-2, FcɣRIIA and PEAR1). Reagents based on nanobodies will increase our understanding of platelet activation in the laboratory.

Research 52

Research Reagent In-Vivo Antibody 52

STAT News

AUGUST 26, 2022

This time around, we note that  Ansa Biotechnologies hired Jeremiah Hanes as senior vice president, research and development. Previously, he worked at PacBio, where he was most recently vice president, reagents R&D. And here is our regular feature in which we highlight a different person each week.

Reagent 98

Reagent Development Research 98

Drug Discovery World

MARCH 27, 2023

Learn more about the trends, insights, and perspectives from ACROBiosystems as a manufacturer of cell therapy reagents, including topics like: CAR-NK research Developing new CAR constructs Evaluation CAR expression detection Role of GMP Manufacturing in cell therapy Download now.

Reagent 52

Reagent Manufacturing Development Research 52

Scienmag

OCTOBER 15, 2020

LIN Wenchu from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science developed a synthesis of metal-free multifunctional therapeutic reagents, called graphitic carbon nitride quantum dots embedded in carbon nanosheets (CNQD-CN), via a one-step hydrothermal treatment. WANG Hui and Prof.

Reagent 85

Reagent Scientist Development Research 85

Drug Discovery World

MAY 25, 2023

The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos. It is accessible, boosts developer productivity and aims to save up to 80% of the time and cost associated with traditional API management strategies.

Production 52

Production Reagent DNA Drugs 52

Roots Analysis

AUGUST 29, 2023

Raw materials used for the production of cell therapies include culture media, growth factors, extracellular matrices and reagents. During the development of these therapies, raw material changes can be expected and the impact of these modifications on the final product must be assessed.

Reagent 52

Reagent Manufacturing Production Containment 52

Drug Discovery World

MARCH 27, 2023

Cell therapy research has never been more exciting with all of the research ongoing.

Reagent 52

Reagent Manufacturing Development Drugs 52

Worldwide Clinical Trials

SEPTEMBER 29, 2022

a typical format is: receptor/target as capture with a generic binding reagent as detection (e.g., If so, it’s important to plan for development of this assay as within the project timeline. For studies of humanized therapeutics (monoclonal antibodies [mAb], fusion protein, antibody-drug conjugates [ADC], bispecific antibodies, etc.),

Reagent 130

Reagent Clinical Trials Clinical Trials Antibody 130

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Uharek is a hematologist and cell and gene therapy specialist at Berlin’s Charité Hospital. .

Development 52

Development Gene Therapy Manufacturing Gene 52

BioTech 365

DECEMBER 15, 2021

Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of … Continue reading → Teknova to Join the Nasdaq Biotechnology Index Teknova to Join the Nasdaq Biotechnology Index HOLLISTER, Calif., 15, 2021 (GLOBE NEWSWIRE) — Alpha Teknova, Inc.

Reagent 40

Reagent Production Development 40

BioTech 365

NOVEMBER 16, 2021

Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of … Continue reading → Teknova to Participate in Upcoming Investor Conferences Teknova to Participate in Upcoming Investor Conferences HOLLISTER, Calif., 16, 2021 (GLOBE NEWSWIRE) — Alpha Teknova, Inc.

Reagent 40

Reagent Production Development 40

Drug Discovery World

NOVEMBER 2, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 26, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 19, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 12, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

SEPTEMBER 15, 2022

In the second article, Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development. In the first article, Marjie Hadad talks to cell therapy expert and Kadimastem CEO Asaf Shiloni about the potential of cell therapy.

Reagent 52

Reagent Production Drugs Development 52

Drug Discovery World

SEPTEMBER 15, 2022

In the second article, Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development. In the first article, Marjie Hadad talks to cell therapy expert and Kadimastem CEO Asaf Shiloni about the potential of cell therapy.

Reagent 52

Reagent Production Drugs Development 52

pharmaphorum

NOVEMBER 26, 2020

The platform is reagent agnostic, meaning that disruption in supply chains can be mitigated by a shift to different reagent suppliers without it calling for wholesale infrastructure change at Salient’s labs, therefore limiting disruption and costs.

Reagent 84

Reagent Vaccination Vaccine Development 84

Pharmaceutical Technology

SEPTEMBER 14, 2022

Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development. Technologies in the delivery of peptides and proteins.

Protein 130

Protein Marketing Manufacturing Reagent 130

BioTech 365

AUGUST 16, 2021

SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline Additional research reagents to detect mutations associated with delta variant of concern now available SYDNEY–(BUSINESS WIRE)–#COVID19–SpeeDx Pty.

Reagent 52

Reagent Development Research 52

BioTech 365

SEPTEMBER 8, 2020

an industry pioneer in developing and commercializing diagnostic products and reagents for hematological malignancies, announced today key members of the leadership team hired to direct Invivoscribe Therapeutics, Inc., its fully integrated drug development engine. Invivoscribe Therapeutics … Continue reading →

Reagent 52

Reagent Engineer Production Development 52

BioTech 365

AUGUST 6, 2020

Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva CAMBRIDGE, England & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it … Continue reading →

Manufacturing 52

Manufacturing Reagent Development 52

BioTech 365

FEBRUARY 23, 2021

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →

Life Science 52

Life Science Genome Genomics Licensing 52

Drug Discovery World

FEBRUARY 6, 2023

CAS SciFinder is designed to provide solutions to challenges encountered in scientific research and discovery, across multiple stages of research and development, including reactions, synthesis, and relevant reference searching.

Reagent 52

Reagent Drugs Medicine Research 52

BioTech 365

SEPTEMBER 7, 2020

Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus CAMBRIDGE & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce … Continue reading →

Reagent 52

Reagent Research Development 52

BioTech 365

OCTOBER 7, 2020

Ten new monoclonal antibodies recognise distinct Spike protein epitopes on SARS-CoV-2 Antibodies available are specific for S1, S2 and receptor-binding domain regions of SARS-CoV-2 Spike protein Different epitopes support identification of matched-pair reagents for immunoassay development OXFORD, England–(BUSINESS WIRE)–The Native … (..)

Antibody 52

Antibody Reagent Protein Development 52